E. Shelley Hwang
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Role of Immune Disruption in Breast Cancer Progression
Open Date: 2026-10-01
Close Date: 2027-09-30
Grant: Close
Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET), for low-risk DCIS
Open Date: 2024-10-01
Close Date: 2025-09-30
Grant: Close
Hwang, S_2024 Impact Report
Open Date: 2024-03-26
Close Date: 2024-03-26
Grant: Close
Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET), for low-risk ductal carcinoma in situ (DCIS)
Open Date: 2023-10-01
Close Date: 2024-09-30
Grant: Close
Molecular and Radiologic Predictors of Invasion in a DCIS Active Surveillance Cohort
Open Date: 2021-10-01
Close Date: 2022-09-30
Articles (12)
Dedifferentiation programs are commonly enacted during breast cancer progression to enhance tumor cell fitness. Increased cellular plasticity within the neoplastic compartment of tumors correlates with disease aggressiveness, often culminating in greater resistance to cytotoxic therapies or augmented metastatic potential. In this study, we found that subpopulations of dedifferentiated neoplastic breast epithelial cells express canonical leukocyte cell surface receptor proteins and have thus named this cellular program “immune mimicry.” Analysis of public human breast tumor single-cell RNA sequencing datasets and histopathologic breast tumor specimens, as well as functional experiments in vitro in breast cancer cell lines and in vivo in murine transgenic and cell line–derived mammary cancer models, showed that neoplastic cells engaged in immune mimicry. Immune-mimicked neoplastic cells harbored hallmarks of dedifferentiation and were enriched in treatment-resistant and high-grade breast tumors. In aggressive breast cancer cell lines, antiproliferative cytotoxic chemotherapies drove epithelial cells toward immune mimicry. The expression of the CD69 leukocyte activation protein by neoplastic cells conferred a proliferative advantage that facilitated early tumor growth. Together, these findings suggest that neoplastic breast epithelial cells upregulating leukocyte surface receptors potentiate malignancy and that neoplastic immune mimicry has potential clinical utility for patient prognosis and stratification. Significance: A subset of neoplastic breast epithelial cells express surface receptors canonically attributed to leukocytes and are associated with therapy resistance and aggressive tumor behavior.
Year:
2026
Clusters of cells expressing mammary keratins and identification of mammary epithelial cells in reduction mammoplasty samples from the Pal and colleagues and Kumar and colleagues scRNA-seq datasets
Year:
2026
Year:
2025
Year:
2025
Preinvasive breast cancer, or ductal carcinoma in situ (DCIS), shares many morphologic and genomic features with invasive breast cancer, yet most DCIS tumors remain indolent over decades. In this study, we performed spatial analyses of somatic mutation patterns in 18 DCIS tumors to infer the underlying growth dynamics. Experimental data combined with mathematical models and Bayesian computation revealed a growth model that mimics the cellular dynamics of branching morphogenesis, which governs normal mammary gland development during puberty. Unlike a traditional model of clonal evolution, this noncompetitive growth model allowed for extensive DCIS spread without the selective pressures of subclone competition that promote the emergence of invasive phenotypes. This finding provides a framework to understand the biological basis for the limited progression of DCIS and adds rationale for ongoing clinical efforts to reduce DCIS overtreatment. Significance: The spatial mutation landscape in ductal carcinoma in situ supports a noncompetitive growth model mirroring normal branching morphogenesis, which has implications for managing low-risk patients and for cancers in other branching organs. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .
Year:
2025
The Supporting Methods describe mathematical modeling and statistical inference methods for DCIS growth, including stochastic ductal tree generation, the Comet and canonical expansion models, and approximate Bayesian computation for model fitting and selection.
Year:
2025
Dedifferentiation programs are commonly enacted during breast cancer progression to enhance tumor cell fitness. Increased cellular plasticity within the neoplastic compartment of tumors correlates with disease aggressiveness, often culminating in greater resistance to cytotoxic therapies or augmented metastatic potential. In this study, we found that subpopulations of dedifferentiated neoplastic breast epithelial cells express canonical leukocyte cell surface receptor proteins and have thus named this cellular program “immune mimicry.” Analysis of public human breast tumor single-cell RNA sequencing datasets and histopathologic breast tumor specimens, as well as functional experiments in vitro in breast cancer cell lines and in vivo in murine transgenic and cell line–derived mammary cancer models, showed that neoplastic cells engaged in immune mimicry. Immune-mimicked neoplastic cells harbored hallmarks of dedifferentiation and were enriched in treatment-resistant and high-grade breast tumors. In aggressive breast cancer cell lines, antiproliferative cytotoxic chemotherapies drove epithelial cells toward immune mimicry. The expression of the CD69 leukocyte activation protein by neoplastic cells conferred a proliferative advantage that facilitated early tumor growth. Together, these findings suggest that neoplastic breast epithelial cells upregulating leukocyte surface receptors potentiate malignancy and that neoplastic immune mimicry has potential clinical utility for patient prognosis and stratification. Significance: A subset of neoplastic breast epithelial cells express surface receptors canonically attributed to leukocytes and are associated with therapy resistance and aggressive tumor behavior.
Year:
2025
Ductal carcinoma in situ (DCIS) is a risk factor for subsequent invasive breast cancer (IBC). To identify events in DCIS that lead to invasive cancer, we performed single-cell RNA sequencing on DCIS lesions and matched normal breast tissue. Inferred copy-number variation was used to identify neoplastic epithelial cells from clinical specimens, which contained a mixture of DCIS and normal ducts. Phylogenetic analysis demonstrated intratumoral clonal heterogeneity that was associated with significant gene expression differences. Classification of epithelial cells into mammary cell states revealed that subclones contained a mixture of cell states, suggesting an ongoing pattern of differentiation after neoplastic transformation. Cell state proportions were significantly different based on estrogen receptor expression, with estrogen receptor–negative DCIS more closely resembling the distribution in the normal breast, particularly with respect to cells with basal characteristics. Specific alterations in cell state proportions were associated with progression to invasive cancer in a cohort of DCIS with longitudinal outcome. Ongoing transcription of key basement membrane (BM) genes occurred in specific subsets of epithelial cell states, including basal/myoepithelial, which are diminished in DCIS. In the transition to IBC, the BM protein laminin, but not COL4, was altered in DCIS adjacent to invasion. Loss of COL4, but not laminin, in an in vitro DCIS model led to an invasive phenotype. These findings suggest that the process of invasion is a loss-of-function event due to an imbalance in critical cell populations essential for BM integrity rather than a gain of an invasive phenotype by neoplastic cells. Significance: Single-cell analyses reveal ductal carcinoma in situ comprises multiple genetic clones with significant phenotypic diversity and link alterations in epithelial cell states and basement membrane integrity with invasive breast cancer progression.
Year:
2025
Although generally unknown, the age of a newly diagnosed tumor encodes valuable etiologic and prognostic information. Here, we estimate the age of breast cancers, defined as the time from the start of growth to detection, using a measure of epigenetic entropy derived from genome-wide methylation arrays. Based on an ensemble of neutrally fluctuating CpG (fCpG) sites, this stochastic epigenetic clock differs from conventional clocks that measure age-related increases in methylation. We show that younger tumors exhibit hallmarks of aggressiveness, such as increased proliferation and genomic instability, whereas older tumors are characterized by elevated immune infiltration, indicative of enhanced immune surveillance. These findings suggest that the clock captures a tumor's effective growth rate resulting from the evolutionary-ecological competition between intrinsic growth potential and external systemic pressures. Because of the clock’s ability to delineate old and stable from young and aggressive tumors, it has potential applications in risk stratification of early-stage breast cancers and guiding early detection efforts.
Year:
2024
Although generally unknown, the age of a newly diagnosed tumor encodes valuable etiologic and prognostic information. Here, we estimate the age of breast cancers, defined as the time from the start of growth to detection, using a measure of epigenetic entropy derived from genome-wide methylation arrays. Based on an ensemble of neutrally fluctuating CpG (fCpG) sites, this stochastic epigenetic clock differs from conventional clocks that measure age-related increases in methylation. We show that younger tumors exhibit hallmarks of aggressiveness, such as increased proliferation and genomic instability, whereas older tumors are characterized by elevated immune infiltration, indicative of enhanced immune surveillance. These findings suggest that the clock captures a tumor’s effective growth rate resulting from the evolutionary-ecological competition between intrinsic growth potential and external systemic pressures. Because of the clock’s ability to delineate old and stable from young and aggressive tumors, it has potential applications in risk stratification of early-stage breast cancers and guiding early detection efforts.
Year:
2024
Year:
2024
Year:
2022
Collaborators (18)
Aashrith Saraswathibhatla
Assistant Professor
University of Minnesota
Gordon Mills
Professor
Oregon Health & Science University
Kouros Owzar
Professor
Duke University
Lars Grimm
Associate Professor
Duke University
Robert B. West
Stanford University School of Medicine
Graham A. Colditz
Chief, Division of Public Health Sciences
Washington University in St. Louis
Chunfang zhu
Stanford University School of Medicine
Carlo Maley
Professor
Arizona State University
Xiaodi Qin
Duke University
Aziz Khan
Assistant Professor
Mohamed Bin Zayed University of Artificial Intelligence
Christina Curtis
Professor of Medicine & Genetics
Stanford University
Rachel Factor
Associate Professor
Duke University Health System
Pepper Schedin
Professor
Oregon Health & Science University
Siri Strand
Assistant professor
Aarhus Universitetshospital
Joseph Geradts
Clinical Professor
East Carolina University
Ovijit Chaudhuri
Associate Professor
Stanford University
Joseph Y. Lo
Professor
Duke University
Shu Jiang
Associate Professor
Washington University in Saint Louis School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.